Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KDM4A | O75164 | 1/20 | 0.30 |
| ▸ | TDP2 | O95551 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2493892 | 0.71 | MAP3K14 (0.44) | MEN1KMT2A | |
| SCHEMBL131785 | 0.66 | MEN1 (0.38) | MEN1KDM4ATDP2KMT2AKDM4C | |
| SCHEMBL28538598 | 0.65 | — | — | |
| SCHEMBL15778628 | 0.64 | — | — | |
| Ammonia Solution, Strong SCHEMBL7125861 | 0.64 | MEN1 (0.37) | MEN1KDM4ATDP2KMT2AKDM4C | |
| SCHEMBL48367 | 0.64 | — | — | |
| SCHEMBL16349234 | 0.64 | — | — | |
| SCHEMBL4997881 | 0.64 | — | — | |
| SCHEMBL4316335 | 0.64 | — | — | |
| Water SCHEMBL6481817 | 0.64 | MEN1 (0.37) | MEN1KDM4ATDP2KMT2AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190133985-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS | Orbus Therapeutics, Inc. | 2019-05-09 | — | — | US | claimed |
| CN-105492011-A | Therapeutic synergy of undesirable chemical compounds | BROWN DENNIS M | 2016-04-13 | — | — | CN | claimed |
| US-20160045502-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2016-02-18 | — | — | US | claimed |
| EP-2983674-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | Brown, Dennis M. (US) | 2016-02-17 | — | — | EP | claimed |
| WO-2014168986-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2014-10-16 | — | — | WO | claimed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2022-11-08 | — | — | US | disclosed |
| US-20190133985-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS | Orbus Therapeutics, Inc. | 2019-05-09 | — | — | US | disclosed |
| CN-105492011-A | Therapeutic synergy of undesirable chemical compounds | BROWN DENNIS M | 2016-04-13 | — | — | CN | disclosed |
| US-20160045502-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2016-02-18 | — | — | US | disclosed |
| EP-2983674-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | Brown, Dennis M. (US) | 2016-02-17 | — | — | EP | disclosed |
| WO-2014168986-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2014-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | MEN1 2187/4885KDM4A 1113/4885TDP2 191/4885 |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | MEN1 2187/4885KDM4A 1113/4885TDP2 191/4885 |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | MEN1 2187/4885KDM4A 1113/4885TDP2 191/4885 |
| US-20160045502-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | MEN1 2187/4885KDM4A 1113/4885TDP2 191/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | MEN1 2187/4885KDM4A 1113/4885TDP2 191/4885 |
| US-20190133985-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS | AHCY, SRM, MAT2A | MEN1 1116/4885KDM4A 970/4885TDP2 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.